medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 4

<< Back Next >>

Med Int Mex 2022; 38 (4)

Hepatitis C in people who inject drugs in Mexico: an overview

Sánchez-Herrera D, Mellado-Orellana R, Rodríguez-Aguilar EF

Language: Spanish
References: 28
Page: 859-867
PDF size: 216.30 Kb.


ABSTRACT

Hepatitis C virus infection (HCV) affects approximately 70 million people. It is estimated that 250 million people have used an illicit drug; about 29.5 million of those consumers suffer from disorders caused by the use of drugs. Infections are among the adverse outcomes for people who inject drugs, which represents an increased risk for HCV. Most drug users who become infected with HCV do so as young adults, which represents more years of medical care. Young adults are the most productive, which would also affect the economy and productivity of the country. The rapid detection programs in places of risk are an excellent option for the global prevention of HCV. Currently, treatment with direct-acting antivirals is considered for all populations, including high risk, such as injectable drug users.


REFERENCES

  1. Blach S, Zeuzem S, Manns M, Altraif I, Duberg AS, MuljonoDH, et al. Global prevalence and genotype distribution ofhepatitis C virus infection in 2015: a modelling study. LancetGastroenterol Hepatol 2017; 2 (3): 161-176. https://doi.org/10.1016/S2468-1253(16)30181-9.

  2. Mercadillo RE, Enciso F. Cuadernos de Trabajo del Monitordel Programa de Política de Drogas 23. 1ª ed. 2017. www.politicadedrogas.org; www.cide.edu.

  3. Guía para comenzar y gestionar programas de intercambiode agujas y jeringas. Organización Mundial de la Salud,Departamento de VIH/SIDA. Organización Mundial de laSalud, 2013.

  4. Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz;Instituto Nacional de Salud Pública, Comisión Nacional Contralas Adicciones, Secretaría de Salud. Encuesta Nacional deConsumo de Drogas, Alcohol y Tabaco 2016-2017: Reportede Drogas. Villatoro-Velázquez JA, Resendiz-Escobar E,Mujica-Salazar A, Bretón-Cirett M, Cañas-Martínes V, Soto-Hernández I, Fregoso-Ito D, Fleiz-Bautista C, Medina-MoraME, Gutiérrez-Reyes J, Franco-Nuñez A, Romero-MartínezM, Mendoza-Alavarado L. Ciudad de México: INPRFM 2017.

  5. Miller AC, Polgreen PM. Many opportunities to record,diagnose, or treat injection drug–related infections aremissed: A population-based cohort study of inpatientand emergency department settings. Clin Infect Dis 2018;52242 (Xx): 1-10. https://doi.org/10.1093/cid/ciy632.

  6. Magis-Rodríguez C, García-Sánchez JA, Marín-NavarreteR. Harm reduction among people who inject drugs inMexico. Salud Mental 2018; 41 (4): 153-156. https://doi.org/10.17711/SM.0185-3325.2018.023.

  7. Marisol Valenzuela-Lara. Estimación de seroprevalenciade anticuerpos anti-VHC en personas con VIH de entre20 y 49 años de edad en tratamiento antirretroviral en laSecretaría de Salud. Boletín Atención Integral de Personacon VIH 2017; 3 (1).

  8. Degenhardt L, Charlson F, Stanaway J, Larney S, AlexanderLT, Hickman M, et al. Estimating the burden of diseaseattributable to injecting drug use as a risk factor for HIV, hepatitisC, and hepatitis B: findings from the Global Burden ofDisease Study 2013. Lancet Infect Dis 2016; 16 (12): 1385-1398. https://doi.org/10.1016/S1473-3099(16)30325-5.

  9. White EF, Garfein RS, Brouwer KC, et al. Prevalence ofhepatitis C virus and HIV infection among injection drugusers in two Mexican cities bordering the U.S. Salud PublicaMex 2007; 49: 165-72.

  10. Liang TJ, Ward JW. Hepatitis C in injection-drug users - Ahidden danger of the opioid epidemic. N Engl J Med 2018;378 (13): 1169-1171. doi: 10.1056/NEJMp1716871.

  11. Guía para comenzar y gestionar programas de intercambiode agujas y jeringas. Organización Mundial de la Salud,Departamento de VIH/ SIDA. Organización Mundial dela Salud 2013.

  12. Tyrfingsson T, Runarsdottir V, Hansdottir I, et al. Markedreduction in the prevalence of hepatitis C viremia amongpeople who inject drugs during 2nd year of the Treatmentas Prevention (TraP HepC) program in Iceland. J Hepatol2018; 68 (Supplement 1): S52. http://dx.doi.org/10.1016/S0168-8278(18)30325-8.

  13. Poo-Ramírez JL, Borjas-Almaguer OD, Kershenobich-Stalnikowitz D, Marín-López E, Flores-Calderón J, Trejo-Estrada R, González-Huezo MS. Consenso Mexicanopara el Tratamiento de la Hepatitis C. Rev GastroenterolMéxico 2018; 83 (3): 275-324. https://doi.org/10.1016/j.rgmx.2017.11.001.

  14. Pawlotsky JM, Negro F, Aghemo A, Berenguer M, DalgardO, Dusheiko G, Wedemeyer H. EASL Recommendationson Treatment of Hepatitis C 2018. J Hepatol 2018; 6 9 (2):461-511. https://doi.org/10.1016/j.jhep.2018.03.026.

  15. Actualización de la guía para la hepatitis C 2018: recomendacionesde AASLD-IDSA para probar, controlar y tratarla infección por el virus de la hepatitis C. EnfermedadesInfecciosas Clínicas 2018; 67 (10): 1477-1492.

  16. Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-AlmaguerOD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N,Flores-Gaxiola A. Consenso Mexicano para el Tratamientode la Hepatitis C. Rev Gastroenterol Méx 2018; 83 (3):275-324. DOI: 10.1016/j.rgmx.2017.11.001.

  17. Bruneau J, Dalgard O, Grebely J, Bruggmann P, Litwin A,Dore GJ, Backmund M. Contradictory advice for peoplewho inject drugs in the 2016 EASL Recommendations onTreatment of Hepatitis C. J Hepatol 2017; 66 (5): 1101-1103.https://doi.org/10.1016/j.jhep.2016.12.028.

  18. Martinello M, Hajarizadeh B, Grebely J, Dore GJ, MatthewsGV. HCV cure and reinfection among people with HIV/HCVcoinfection and people who inject drugs. Current HIV/AIDS Rep 2017; 14 (3): 110-121. https://doi.org/10.1007/s11904-017-0358-8.

  19. Mathur P, Kattakuzhy S, Rosenthal E, Masur H, Nussdorf L,Kottilil S, Chaudhury C. Collocation of Buprenorphine withHCV treatment to improve adherence and reduce harmin PWID with HCV: Preliminary data from the ANCHORstudy. J Hepatol 2018; 68: S51. https://doi.org/10.1016/s0168-8278(18)30322-2.

  20. Grebely J, Dalgard O, Conway B, Cunningham EB, BruggmannP, Hajarizadeh B, Dore GJ. Sofosbuvir and velpatasvirfor hepatitis C virus infection in people with recentinjection drug use (SIMPLIFY): an open-label, single-arm,phase 4, multicentre trial. Lancet Gastroenterol Hepatol2018; 3 (3): 153-161. https://doi.org/10.1016/S2468-1253(17)30404-1.

  21. Valdez-Hernández P, Rodríguez-Aguilar EF, Páez-ZayasVM, Lizárraga-Gómez E, García-Juárez I. Propuesta de unesquema simple de antivirales de acción directa para tratamientode VHC en un sistema de salud público con bajopresupuesto. Salud Publica Mex 2018; 60 (6): 738-740.https://doi.org/10.21149/9492.

  22. Burra P, Burroughs A, Graziadei I, Pirenne J, Valdecasas JC,Muiesan P, Forns X. EASL clinical practice guidelines: livertransplantation. J Hepatol 2016; 64 (2): 433-485.

  23. Hill A, Riley RD, Simmons B, Saleem J, Cooke GS. Risk of laterelapse or reinfection with hepatitis C virus after achievinga sustained virological response: a systematic review andmeta-analysis. Clin Infect Dis 2016; 62 (6): 683-694. https://doi.org/10.1093/cid/civ948.

  24. Goldberg DS, Blumberg E, McCauley M, Abt P, Levine M.Improving organ utilization to help overcome the tragediesof the opioid epidemic. Am J Transplant 2016; 16 (10):2836-2841. https://doi.org/10.1111/ajt.13971.

  25. Segev DL, Sulkowski M, Bowring MG, Durand CM, Thomas AG,Desai NM, Kucirka LM. The drug overdose epidemic and deceased-donor transplantation in the United States. Ann InternMed 2018; 168 (10): 702. https://doi.org/10.7326/m17-2451.

  26. Terrault N, Chhatwal J, Chung RT, Samur S, Kanwal F, RobertsMS, Ayer T. Cost effectiveness of transplanting HCVinfectedlivers into uninfected recipients with preemptiveantiviral therapy. Clin Gastroenterol Hepatol 2018. https://doi.org/10.1016/j.cgh.2018.08.042.

  27. Centro Nacional de Trasplantes. Reporte anual de donacióny Trasplantes en México. http://cenatra.salud.gob.mx/transparencia/trasplante_estadisticas.html

  28. Mendoza-Sánchez F. Trasplante hepático en México. RevMex Trasplantes 2018; 7 (1): 25-30.




2020     |     www.medigraphic.com